Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

金迪克(688670.SH)披露2025年度业绩快报，公司2025年营业收入1.13亿元，同比增长40.13%;归属于母 公司所有者的净利润亏损1.73亿元，上年同期亏损9350.28万元。 报告期内，营业收入同比增长40.13%，主要系公司提前排产，各部门协调配合，提升生产效率，加快 了流感疫苗生产和批签发节奏，解决出货晚影响发货问题，同时深入客户服务，持续优化营销管理体 系，拓展新的增量市场，提高产品覆盖率。营业利润、利润总额、归属于母公司所有者的净利润、归属 于母公司所有者的扣除非经常性损益的净利润、基本每股收益、加权平均净资产收益率等各项指标在报 告期内变动幅度较大，主要系公司研发投入大幅增加、计提资产减值准备和存货报废等因素影响所致。 ...

报告期内，营业收入同比增长40.13%，主要系公司提前排产，各部门协调配合，提升生产效率，加快 了流感疫苗生产和批签发节奏，解决出货晚影响发货问题，同时深入客户服务，持续优化营销管理体 系，拓展新的增量市场，提高产品覆盖率。营业利润、利润总额、归属于母公司所有者的净利润、归属 于母公司所有者的扣除非经常性损益的净利润、基本每股收益、加权平均净资产收益率等各项指标在报 告期内变动幅度较大，主要系公司研发投入大幅增加、计提资产减值准备和存货报废等因素影响所致。 金迪克(688670.SH)披露2025年度业绩快报，公司2025年营业收入1.13亿元，同比增长40.13%;归属于母 公司所有者的净利润亏损1.73亿元，上年同期亏损9350.28万元。 ...

格隆汇2月12日丨金迪克(688670.SH)公布2025年度业绩快报，公司2025年实现营业收入1.13亿元，同比 增长40.13%；实现归属于母公司所有者的净利润-1.73亿元，同比增亏85.53%；实现归属于母公司所有 者的扣除非经常性损益的净利润-1.8亿元，同比增亏69.46%。 报告期内，营业收入同比增长40.13%，主要系公司提前排产，各部门协调配合，提升生产效率，加快 了流感疫苗生产和批签发节奏，解决出货晚影响发货问题，同时深入客户服务，持续优化营销管理体 系，拓展新的增量市场，提高产品覆盖率。 ...

产品研发进展 四价流感病毒裂解疫苗(儿童)项目：III期临床试验受试者已全部完成入组，并完成疫苗接种，目前血清 正在中国食品药品检定研究院检验，等待后续结果。 三价流感病毒裂解疫苗：上市生产申请已获受理，并完成注册检验、标准复核等程序，目前等待国家药 品监督管理局药品审评中心的进一步审评结果。这些审评进展可能影响公司未来产品线拓展。 财务状况 经济观察网金迪克(688670)近期公告显示，公司2025年业绩预亏，主要因研发投入增加及计提资产减值 准备和存货报废处置。同时，其疫苗研发项目取得阶段性进展。 业绩经营情况 公司已于2026年1月30日发布业绩预告，预计2025年归属于上市公司股东的净利润亏损1.6亿元至1.8亿 元，同比增亏。主要原因是研发投入增加及计提资产减值准备和存货报废处置约4,199.96万元。投资者 可关注后续年度报告的正式披露，以获取经审计的财务细节。 公司2025年度计提资产减值准备及部分存货报废处置合计约4,199.96万元，该事项已影响当期利润，投 资者可关注年度报告中对此的详细说明及潜在财务调整。 此外，公司曾于2026年1月26日因股价波动登上龙虎榜，但此类事件属短期市场行为。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司2025年年度的定期报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 注：1.本报告期初数同法定披露的上年年末数。 证券代码：688670 证券简称：金迪克 公告编号：2026-003 江苏金迪克生物技术股份有限公司 2025 年度业绩快报公告 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 公司 2025 年实现营业收入 11,323.18 万元，同比增长 40.13%；实现归属于 母公司所有者的净利润-17,347.36 万元，同比增亏 85.53%；实现归属于母公司所 有者的扣除非经常性损益的净利润-18,000.28 万元，同比增亏 69.46%。 截至 2025 年 12 月 31 日，公司总资产 142,189.87 万元，较报告期初下降 7.24%；归属于母公司的所有者权益 109,998.72 万元，较报告期初下降 13.90%。 报告期内 ...

金迪克发布业绩快报，2025年营业收入1.13亿元，同比增长40.13%；净利润亏损1.73亿元，上年同期亏 损9350.28万元。 ...

Core Viewpoint - The company emphasizes the importance of balancing short-term interests with long-term development in its profit distribution strategy, considering various factors such as industry characteristics and operational model [2]. Group 1 - The company will take into account industry characteristics, development stage, operational model, profitability, and significant capital expenditure plans when deciding on profit distribution [2]. - The board of directors is committed to making prudent decisions that align with shareholder interests [2]. - The company plans to disclose its annual report on April 29, 2026, which will provide specific performance details [2].

Core Viewpoint - Shenzhen's Bao'an District is accelerating the development of a new quality imaging industry by integrating culture and technology, aiming for over 100 billion yuan in revenue from the digital creative industry cluster by 2030 [1]. Group 1: Industry Development - Bao'an has 262 imaging-related companies, with over 95% being hardware manufacturers, and aims to enhance the synergy between content creation and hardware/software innovation [2]. - The digital creative industry cluster in Bao'an generated an added value of approximately 6.506 billion yuan in the first three quarters of 2025, with a growth rate of 30.76% [2]. - The district has launched measures to support high-quality development in the new quality imaging industry, covering key areas such as space, technology, platforms, and finance [3]. Group 2: Technological Innovation - Bao'an is focusing on the development of smart glasses as a key hardware component of the new quality imaging industry, with a goal of gathering over 100 industry chain companies by the end of 2027 [3]. - The district has identified 54 application scenarios and 48 enterprise technology capabilities to create a closed-loop mechanism for demand response and project implementation [6]. - The introduction of the digital human image "Wanbao" aims to enhance Bao'an's cultural tourism identity and will be widely applied in local tourism scenarios [6]. Group 3: Ecosystem Building - Bao'an is establishing the "Shenzhen (Bao'an) New Quality Imaging Industry Alliance" to integrate the industry chain, innovation chain, funding chain, and talent chain [9]. - The alliance has already connected with over 40 key enterprises and universities, focusing on building a complete ecosystem from technology to content [9]. - Bao'an aims to create a supportive environment for enterprises, facilitating collaboration and innovation within the new quality imaging industry [10].

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The vaccine industry is currently facing short-term performance pressure due to weak demand and structural oversupply, with many companies experiencing declines or losses in performance [1][7][8] - Despite the challenges, innovation and international expansion are ongoing, providing potential for medium to long-term growth [1][8] - The industry is transitioning from scale expansion to innovation-driven growth, with policy, demand, and technology as the three main driving factors for development [8][24][26] Summary by Sections Domestic and International Vaccine Dynamics - Kanghua Biotech has initiated Phase I clinical trials for its six-valent norovirus vaccine, which theoretically can prevent over 90% of norovirus infections [1] - Wantai Biopharma's bivalent HPV vaccine has successfully passed the WHO PQ periodic review [1] - Zhifei Biological's application for clinical trials of a freeze-dried inactivated vaccine for Japanese encephalitis has been accepted [1] Performance Forecasts - Chengda Bio expects a 59.34%-63.98% decrease in net profit for 2025 compared to the previous year [1] - CanSino anticipates a revenue increase of 22.88%-27.61% for 2025, with a turnaround in net profit [1] - Watson Bio forecasts a revenue of 2.4-2.43 billion yuan for 2025, a decline of approximately 14.9%-13.9% [1] - Other companies like Kangtai Bio and Wantai Bio also expect significant declines in net profit for 2025 [1] Market Performance - The vaccine sector saw a decline of 1.65% last week, with the overall pharmaceutical industry down 3.31% [2][5] - The vaccine sector has experienced a cumulative decline of 10.08% since the beginning of 2025 [5][13] Valuation Metrics - The vaccine sector's PE (ttm) is 92.01X, down 1.88X from the previous week, while the PB (lf) is 1.78X, down 0.04X [6] - The PE is at the 55.99% percentile since 2013, and the PB is at the 1.28% percentile since 2013 [6] Investment Recommendations - The vaccine industry is still under pressure, but companies are actively adjusting their pipeline strategies, focusing on technological innovation and multi-valent products [7][8] - Long-term prospects remain positive due to innovation and international market expansion, with a recommendation to focus on companies with strong R&D capabilities and differentiated product offerings, such as CanSino [8][26]